Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06858566

Impact of the Kaligo Solution on Learning to Write in Children Aged 6 to 11 With Handwriting Disorders : KALIGO+

Impact of the Kaligo Solution on Learning to Write in Children Aged 6 to 11 With Handwriting Disorders: a Multiple Baseline Online SCED Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
15 (estimated)
Sponsor
Fondation Ildys · Academic / Other
Sex
All
Age
6 Years – 11 Years
Healthy volunteers
Not accepted

Summary

Writing is a fundamental skill, crucial to a child's success at school and the development of independence. Around 30% of children present difficulties in learning to write, and for some of them (10%), these difficulties persist for a long time. Adapted learning can improve their handwriting. Initial studies into the use of new technologies (tablets, virtual reality headsets) have shown that they can help children learn to write. Attractive to children, these interfaces make it possible to apply new paradigms (e.g. enrichment of feedback \[sonification\], variation of writing media) that have proved effective, mainly with children with 'typical' development. The Kaligo+ solution is based on the latest scientific advances to offer an innovative approach to learning to write, particularly for children with significant difficulties in this area. This study proposes to test the benefits of the Kaligo+ solution on 15 children with writing difficulties. The main objective of this pilot study is to demonstrate improved writing performance following use of the Kaligo+ solution in children aged 6 to 11 with writing difficulties, using a Single Case Experimental Design (SCED) methodology.

Conditions

Interventions

TypeNameDescription
OTHERKaligo + scoreThe Kaligo + Score will be taken twice a week during baseline and intervention and once a week during follow-up.

Timeline

Start date
2025-03-21
Primary completion
2027-02-24
Completion
2027-02-24
First posted
2025-03-05
Last updated
2025-03-28

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06858566. Inclusion in this directory is not an endorsement.